» Articles » PMID: 21514759

Development of Hepatocellular Carcinomas in Patients with Absence of Tumors on a Prior Ultrasound Examination

Overview
Journal Eur J Radiol
Specialty Radiology
Date 2011 Apr 26
PMID 21514759
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: To evaluate hepatocellular carcinoma (HCC) that developed in patients with no evidence of a tumor during a prior ultrasound (US) performed within 1 year of the diagnosis.

Methods: We retrospectively analyzed data for 100 consecutive patients with liver cirrhosis who had undergone US within 1 year prior to HCC diagnosis and who showed no liver lesions on the previous US. Size and T stage of HCC were assessed as well as whether patients met surgical criteria for liver transplantation as HCC treatment [Milan or University of California at San Francisco (UCSF) criteria].

Results: The mean interval between the negative and diagnostic scans was 5 months, 13 days. HCC presented as a single nodule in 69 patients (size, 0.8-8.0 cm), as two or more nodules in 18 patients, and as the diffuse form of HCC in 13 patients. HCC presented as a small tumor (<3 cm) in 48 patients. T stages were: T1 in 26 patients, T2 in 45, T3 in 18, and T4 in 11. The Milan criteria were met in 79 patients. Eighty-five patients fulfilled the UCSF.

Conclusion: Patients may present with advanced HCC, even if sonographic findings were negative within 1 year prior to diagnosis.

Citing Articles

Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Krishan S, Dhiman R, Kalra N, Sharma R, Baijal S, Arora A J Clin Exp Hepatol. 2019; 9(5):625-651.

PMID: 31695253 PMC: 6823668. DOI: 10.1016/j.jceh.2019.07.005.


Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.

An C, Kim D, Choi J, Han K, Roh Y, Kim M BMC Cancer. 2018; 18(1):915.

PMID: 30249190 PMC: 6154402. DOI: 10.1186/s12885-018-4827-2.


Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Kagen A, Fowler K, Sirlin C Hepat Oncol. 2018; 1(1):95-105.

PMID: 30190944 PMC: 6114011. DOI: 10.2217/hep.13.11.


Advanced-stage hepatocellular carcinoma presenting without radiographic liver lesions.

Mupamombe C, Veluvolu R, Ahmad A, Preet M, Taiwo E Clin Case Rep. 2018; 6(6):975-982.

PMID: 29881547 PMC: 5985989. DOI: 10.1002/ccr3.1480.


Comparison of biannual ultrasonography and annual non-contrast liver magnetic resonance imaging as surveillance tools for hepatocellular carcinoma in patients with liver cirrhosis (MAGNUS-HCC): a study protocol.

Kim H, Kim K, Choi J, Lee J, Lee C, Kang T BMC Cancer. 2017; 17(1):877.

PMID: 29268722 PMC: 5740703. DOI: 10.1186/s12885-017-3819-y.